News

  1. Phase 2b Data Of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved In Up To 85% Of Treatment-Naive Patients 11/10/2012

    Final Phase 2b data from Boehringer Ingelheim's interferon (IFN)-free Phase 2b SOUND-C2 study showed that up to 85 percent of genotype 1b (GT1b) hepatitis C (HCV) patients achieved sustained virologic response (SVR or viral cure) 12 and 24 weeks after the end of treatment with the investigational treatment regimen of faldaprevir (BI 201335) and BI 207127, in combination with ribavirin (RBV)

  2. Zafgen Announces Initiation Of Phase 2a Clinical Development With Beloranib In Obesity 11/6/2012

    Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced that it has initiated Phase 2a clinical testing of  beloranib.

  3. Extraneous Data Collected In Clinical Trials Cost Drug Developers $4B To $6B Annually, According To Tufts Center For The Study Of Drug Development 11/6/2012

    One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per trial, a newly completed study by the Tufts Center for the Study of Drug Development has found.

  4. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical Trial Of APD811 For Pulmonary Arterial Hypertension 10/12/2012

    Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

  5. VentiRx Pharmaceuticals Announces Exclusive, Strategic Collaboration For Development Of Novel TLR8 Agonist VTX-2337 With Celgene Corporation 10/3/2012

    VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG) for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.

  6. First Results From Phase 3 CANVAS Trial Show Canagliflozin As Add-on Therapy To Insulin Lowered Blood Sugar Levels In Patients With Type 2 Diabetes At An Elevated Risk For Cardiovascular Disease 10/2/2012

    Janssen Research & Development, LLC (Janssen) today announced that use of the investigational medicine canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for type 2 diabetes and who are considered to be at greater risk for cardiovascular disease.

  7. Teva To Initiate Third Phase III Trial Of Oral Laquinimod For The Treatment Of Relapsing Remitting Multiple Sclerosis 8/8/2012

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

  8. Blinded Diagnostics Appoints Jon Klippel As VP, Business Development 7/13/2012

    Blinded Diagnostics recently announced the expansion of their business development efforts by appointing Jon Klippel as the new Vice President of Business Development. Jon, a 25 year veteran of the medical device and diagnostics industry, will be working from the Saddle Brook office to provide point of care diagnostics solutions to pharmaceutical and biopharmaceutical clients.

  9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
  10. Onyx Pharmaceuticals Initiates Phase 3 Kyprolis™ Head-To-Head Comparison Trial vs. Velcade® In Patients With Relapsed Multiple Myeloma 7/2/2012

    Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis™ (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib (Velcade®) with dexamethasone in patients with relapsed multiple myeloma.